PubMed · 1970 · 33 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyDrug MetabolismEnzyme InhibitionMetabolism Of Anticancer Agents5-Fluorouracil TreatmentIrreversible Enzyme InhibitionIrreversible InhibitionIrreversible Inhibition MechanismsReversible Enzyme InhibitionReversible InhibitionSubstrate Binding AffinitySubstrate Binding Specificity
The dehalogenation of 5-iodouracil was studied in vitro , and two inhibitors of the reaction were found. One of these, 5-cyanouracil, previously reported to inhibit dihydrouracil dehydrogenase, was shown in this study to inhibit dehalogenation. The second inhibitor, 5-diazouracil, was shown to be an irreversible inhibitor of dehalogenation, which appears to act at the substrate binding site. Diazouracil was shown to be an effective inhibitor in vivo and may be of value in enhancing tumor therapy, including radiosensitization, with halogenated pyrimidines.